Deal overview
| Target | SPARK THERAPEUTICS INC |
|---|---|
| Bidder | ROCHE HOLDING AG |
| Price | £0.00 Full version or £25.00 Light version |
| Publication Date | Feb 25, 2019 |
| Abstract | On 25 February 2019, the quoted Swiss pharmaceutical group Roche Holding AG ("Roche") announced a recommended public offer for Spark Therapeutics Inc ("Spark Therapeutics"), a quoted US-based gene therapy group. The offer of US$ 114.50 per share valued 100% of Spark Therapeutics at approximately US$ 4.4 billion on an enterprise value basis. The closing of the transaction was ... |
| Number of pages (Full version) | 0 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
